Bristol-Myers Squibb signs exclusive worldwide license agreement with Psioxus Therapeutics

News Image

Bristol-Myers Squibb Company and PsiOxus Therapeutics today announced an agreement granting Bristol-Myers Squibb exclusive worldwide rights to NG-348, a pre-clinical stage, "armed" oncolytic virus with the goal of addressing solid tumours. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

To see the full announcement, click here.

Mercia News